EchoIQ (ASX:EIQ) — New Clinical Data Reinforces Market Potential of EchoSolv™ AS
- Noel Ong
- 1 day ago
- 5 min read
Updated: 1 day ago
Announcement
Severe AS data presented at AHA Scientific Sessions 2025 13 November 2025 (click here to view the announcement)
Echo IQ Limited (ASX: EIQ), based in Sydney, has released new clinical insights presented at the AHA Scientific Sessions 2025 in New Orleans, highlighting the growing medical need and commercial opportunity for EchoSolv AS, the Company’s AI-powered decision-support tool for severe aortic stenosis (AS).
The update is anchored on two major real-world studies involving 30,878 echocardiograms and a broader 1.18 million-patient dataset from the National Echo Database of Australia (NEDA).
The Business of the Company: Focus – AI Decision-Support for Cardiovascular Care
Echo IQ operates in the cardiology decision-support sector, applying advanced analytics and FDA-cleared AI models to improve the diagnosis and management of aortic stenosis. The Company’s flagship product, EchoSolv AS, is built to assist cardiologists in identifying severe AS phenotypes more consistently and accurately across patient subtypes.
Highlights – New Clinical Evidence Strengthens EchoSolv’s Role in Improving AS Diagnosis
1. Investigator-Initiated Study: EchoSolv Outperforms Cardiologists
A University of Notre Dame Australia–led study compared cardiologist reporting against EchoSolv across 30,878 echocardiograms (Figure 1).
Figure 1: EchoSolv vs Cardiologists – Study Design Overview in ‘Accuracy of cardiologist reporting of severe aortic stenosis vs decision-support artificial intelligence and its impact on clinical management’ (source: EIQ)
Key findings include:
EchoSolv demonstrated superior accuracy in identifying severe AS, particularly in women and low-gradient presentations.
The AI restored gender equity, improving diagnosis ratios from 2.2:1 to 1.1:1 (male: female).
Real-time EchoSolv integration could materially reduce delays in diagnosis and intervention, improving clinical outcomes (Figure 2).
Figure 2: Echo report–driven follow-up and intervention outcomes for severe AS patients (investigator-initiated study). (source: EIQ)
2. NEDA Study: 1.18 Million Patients Reveal a Treatment Gap in Standard Care
A national analysis covering 1.2 million echocardiograms revealed:
Only 36% of women and 45% of men with moderate-to-severe AS received intervention.
Significant mismatch between haemodynamic severity and treatment rates.
“Watchful waiting” is contributing to substantial life-years lost, with early intervention being crucial.
The findings emphasise the need for improved monitoring tools like EchoSolv to bridge the diagnostic gap.
Leadership Commentary
Chief Executive Officer, Mr Dustin Haines, commented:
“The cumulative data from the two severe AS studies presented by the University of Notre Dame Australia Researchers at AHA25 have reinforced our commitment to leveraging advanced analytics and AI to transform severe AS care for patients. A key takeaway from the study that reviewed echocardiograms for more than 1.2 million patients is that the ‘watchful waiting’ strategy for moderate-to-severe AS cases is failing many of these patients. In addition, we are excited by the insights from the results that show how EchoSolv AS was able to identify the severe AS phenotype more accurately than cardiologists, particularly in some subtypes of AS. This study was of particular interest as it showed clearly that we have work to do in accurately diagnosing women with aortic stenosis and we are optimistic with the performance of EchoSolv AS to improve the gender equity.”
About Echo IQ and Its AI Platform
Echo IQ is an AI and medical technology company based in Sydney, Australia, using AI-driven technology and proprietary software to improve decision-making in cardiology. Its EchoSolv AS platform has been validated using large, multi-centre datasets, including the National Echo Database of Australia (NEDA), with ongoing clinical research supporting adoption across Australia and the United States.
Near-term Milestones to Watch
Increasing clinical deployments following the AHA25 data presentations.
Expansion of real-world integrations to support cardiologists in major cardiac centres.
Growing alignment with health policy discussions on AS treatment standards.
Continued publication of large-scale validation studies in peer-reviewed environments.
How Samso Understands the Investment Memo for the Company
Echo IQ is positioning EchoSolv AS as a scalable diagnostic aid at a time when AS detection gaps are being increasingly scrutinised. The two AHA25 studies underpin the technology’s relevance across gender groups, clinical settings, and high-risk AS subtypes. The Company’s competitive position is strengthened by FDA clearance, broad data validation, and quantifiable clinical benefits demonstrated at scale.
Samso Concluding Comments
The cardiology sector has long struggled with the limitations of visual interpretation and human variability in echocardiogram reporting. EchoSolv’s performance highlights how AI can complement rather than replace clinicians, ultimately improving patient outcomes.
Both studies presented at AHA25 underscore a systemic challenge: the underdiagnosis and undertreatment of severe aortic stenosis. This is especially true in moderate-to-severe cases where delayed intervention materially affects survival.
Echo IQ’s strategy to drive adoption through real-world validation and investigator-led research is aligned with what clinicians and hospitals typically require before integrating new technologies.
In the longer term, EchoSolv’s value proposition may extend beyond AS, potentially forming a broader AI-enabled cardiology platform supported by Echo IQ’s proprietary datasets.
The Samso Way – Seek the Research
Always understand the story behind the data before making an investment decision.
Our mission is simple: cut through the noise and spotlight what matters—genuine stories, grounded insights, and real opportunity.
Our content is well-researched and is only created if the team sees merit in discussing the company or concept. Investors can explore our three core platforms:
There may be numerous paths to success in investing, but the common thread among successful individuals is that they remain committed to making informed decisions. Equip yourself with the right knowledge and tools, and you will be well on your way to achieving your financial goals.
Most importantly, investors need to be absolutely diligent in understanding their own risk-reward tolerance and capabilities. Never bite off more than you can chew. As they say, Rome wasn’t built in a day, and the Great Wall stood because it took centuries to complete.
The Samso Philosophy:
Stay curious. Stay sharp. And remember—digging deeper always uncovers the real value.
In Life, there is no such thing as a Free Lunch.
Happy Investing, and the only four-letter word you need to know is DYOR.
To support our independent nature of our work, please head over to our Support Page and give us a helping hand in any of the ways listed. This is a new initiate for the Samso Platform, and it was always the concept of Samso when we started this journey in 2018.
Disclaimer
The information or opinions provided herein do not constitute investment advice, an offer or solicitation to subscribe for, purchase or sell the investment product(s) mentioned herein. It does not take into consideration, nor have any regard to your specific investment objectives, financial situation, risk profile, tax position and particular, or unique needs and constraints.
Share to Grow: Your Bonus
Samso has just released an eBook: How to Add Value to your Share Portfolio
A lesson on geological models sought by mining companies that gives insight and an understanding of which portfolios are better - and potentially more lucrative – investments. Click here to download this eBook.
If you find this article informative and useful, please help me share the information. I try to write about topics that are interesting and have the potential to be of investment value. It is not easy to find stories that fit those parameters. If you or your organisation sees the benefit of what Samso is trying to achieve and have a need to share your journey, please contact me at noel.ong@samso.com.au.
Samso is a trusted platform that equips dedicated investors with up-to-date industry knowledge and insights from top CEOs and thought leaders. By staying informed on business advancements and market trends, investors can enhance their financial decisions through a combination of expert guidance and their own research.